AP NEWS
Press release content from BusinessWire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from BusinessWire
Press release content from BusinessWire. The AP news staff was not involved in its creation.

LabConnect Names New COO and Promotes Two Other Executives

June 25, 2018 GMT

SEATTLE--(BUSINESS WIRE)--Jun 25, 2018--LabConnect, LLC, a leading global provider of central laboratory and support services for biopharmaceutical, medical device and contract research organizations, announces the promotion of three executives to top-level management positions: Barry Simms, MBA, as chief operating officer, Trenton Harris, MSM/MBA, as executive vice president and Elizabeth Koury, MS, as vice president, scientific affairs. All three executives bring a wealth of biopharmaceutical industry skills and experience to the company.

Simms, who has applied his experience and skills to support LabConnect’s executive team and the company’s operations in Johnson City, Tenn., will oversee LabConnect’s operations and growth as chief operating officer. Simms began his career over 18 years ago as a clinical research associate and has held positions of increasing responsibility since then.

As executive vice president, Harris brings a diverse skill set and over 20 years of extensive clinical trials experience to LabConnect. Harris combines both deep financial planning and analysis expertise with an understanding of the importance of employee engagement to ensure superior customer service. Prior to LabConnect, Harris was a senior executive in drug development for Covance’s central laboratory and safety division.

Koury joined LabConnect in 2012 following more than 15 years of conducting and overseeing scientific research focused in neuroscience, oncology and immunology. As vice president of scientific affairs, she oversees scientific operations (SciOps) and technical affairs. Koury will accelerate the growth of SciOps and formalize LabConnect’s technical support functions to benefit clients.

“We are pleased to have these three executives on our team and to acknowledge their hard work and ongoing contributions to LabConnect’s success,” said Eric Hayashi, MBA, president and CEO of LabConnect. “Their continued expertise and dedication to our company’s mission creates long-term value for our clients.”

For more information, visit labconnectllc.com.

About LabConnect, LLC Founded in 2002, LabConnect provides global central laboratory and client-inspired support services including routine and specialized laboratory testing, kit building, sample management, data management, biorepository and scientific support services for biopharmaceutical and CRO clients. LabConnect’s unique combination of state-of-the-art technology, world-class laboratories, easy access to major and emerging markets and extensive specialized testing expertise means that drug development companies can rely on one provider for their central laboratory and preclinical through Phase IV clinical development needs. Learn more at labconnectllc.com or connect with LabConnect on LinkedIn.

View source version on businesswire.com:https://www.businesswire.com/news/home/20180625005164/en/

CONTACT: For LabConnect, LLC

Lea Studer, 402-366-1752

SCORR Marketing

lea@scorrmarketing.com

KEYWORD: UNITED STATES NORTH AMERICA TENNESSEE WASHINGTON

INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY CLINICAL TRIALS MEDICAL DEVICES PHARMACEUTICAL RESEARCH SCIENCE

SOURCE: LabConnect, LLC

Copyright Business Wire 2018.

PUB: 06/25/2018 08:00 AM/DISC: 06/25/2018 08:01 AM

http://www.businesswire.com/news/home/20180625005164/en